Senotherapeutic Potential of Araliadiol in Senescent Human Dermal Fibroblasts: An In Vitro Study Using Three...

Area of Science:

• Dermatology and Gerontology
• Cellular Senescence
• Natural Product Therapeutics

Background:

• Growing global population aging necessitates therapies for age-related diseases, particularly skin aging.
• Existing senescence models and photoaging treatments have limitations, driving the search for novel senotherapeutics.
• Araliadiol, a plant-derived compound, is investigated for its potential in combating skin aging.

Purpose of the Study:

• Establish validated dermal fibroblast senescence models (etoposide, H2O2, UVA).
• Investigate the senotherapeutic potential of araliadiol in these models.
• Evaluate araliadiol's senolytic and senomorphic effects on skin aging markers.

Main Methods:

• Senescence induction and validation via cell counting, SA-β-gal staining, and ATP assays.
• Senotherapeutic evaluation using RT-qPCR, Western blotting, immunofluorescence, and ELISA.
• Assessment of senolytic activity with ABT-737 and senomorphic effects of araliadiol.

Main Results:

• Validated senescence models showed increased SA-β-gal, ROS, p16, and p21.
• Araliadiol demonstrated senomorphic effects: reduced SASP gene expression and NF-κB phosphorylation.
• Araliadiol suppressed MMP-1/MMP-3 expression and AP-1 activation, while increasing procollagen type I.

Conclusions:

• Araliadiol exhibits senomorphic, not senolytic, effects in validated dermal fibroblast senescence models.
• The findings support araliadiol's potential as a natural topical agent for mitigating skin aging.
• Araliadiol may offer a novel therapeutic strategy for age-related skin changes.